News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The hospital hosted a two-day event with top internal and external faculty and medical experts
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
Subscribe To Our Newsletter & Stay Updated
